Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2 ) in combination with lenalidomide and dexamethasone

Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m² ) in combination with lenalidomide and dexamethasone

Am J Hematol. 2021 Jun 1;96(6):E193-E196. doi: 10.1002/ajh.26150. Epub 2021 Mar 19.

Neha Korde^{1

2}, Donna Mastey¹, Elizabet Tavitian¹, Sham Mailankody^{1

2}, Alexander Lesokhin^{1

2}, Hani Hassoun^{1

2}, Eric L Smith³, Nikoletta Lendvai¹, Malin Hultcrantz^{1

2}, Urvi Shah^{1

2}, Carlyn Tan^{1

2}, Sydney Lu^{1

2}, Benjamin Diamond¹, Meghan Salcedo¹, Kelly Werner¹, David J Chung^{2

4}, Michael Scordo^{2

4}, Gunjan L Shah^{2

4}, Oscar Lahoud^{2

4}, Heather Landau^{2

4}, Maria Arcila⁵, Caleb Ho⁵, Mikhail Roshal⁵, Ahmet Dogan⁵, Andriy Derkach⁶, Sean M Devlin⁶, Sergio A Giralt^{2

3}, Ola Landgren^{1

7}

¹ Multiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
² Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
³ Medical Oncology, Dana-Farber Cancer Institute, New York, New York, USA.
⁴ Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
⁵ Hematopathology Services, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
⁶ Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
⁷ Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, New York, New York, USA.

No abstract available